Rational design and synthesis of 2,4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non‐small cell …
L Duan, C Chu, X Huang, H Yao, J Wen, R Chen… - Archiv der … - Wiley Online Library
Many patients with non‐small cell lung cancer (NSCLC) initially benefit from epidermal
growth factor receptor (EGFR) targeted therapy. Unfortunately, varying degrees of resistance …
growth factor receptor (EGFR) targeted therapy. Unfortunately, varying degrees of resistance …
Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non-small cell …
L Duan, C Chu, X Huang, H Yao, J Wen… - Archiv der …, 2024 - europepmc.org
Many patients with non-small cell lung cancer (NSCLC) initially benefit from epidermal
growth factor receptor (EGFR) targeted therapy. Unfortunately, varying degrees of resistance …
growth factor receptor (EGFR) targeted therapy. Unfortunately, varying degrees of resistance …
Rational design and synthesis of 2, 4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non-small cell …
L Duan, C Chu, X Huang, H Yao, J Wen… - Archiv der … - pubmed.ncbi.nlm.nih.gov
Many patients with non-small cell lung cancer (NSCLC) initially benefit from epidermal
growth factor receptor (EGFR) targeted therapy. Unfortunately, varying degrees of resistance …
growth factor receptor (EGFR) targeted therapy. Unfortunately, varying degrees of resistance …